Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07159776Not Yet Recruiting

Multiple Digital Biomarkers for Optimization of IBD Care

Role: lead

NCT04408703Completed

PRognOstiC valuE of rEd Density in Ulcerative Colitis

Role: collaborator

NCT04775732Phase 4Completed

Ultra-proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Role: lead

NCT04990245Completed

pAtient rePorted Outcomes Linked With histoLogy in Patients With uLcerative cOlitis

Role: lead

All 4 trials loaded